Quipt Home Medical Corp.
QIPT.V
Toronto Stock Exchange Ventures4.13
CAD
+0.02
- -
Quipt Home Medical Corp.
QIPT.V
(Toronto Stock Exchange Ventures)
Recent
price
4.13
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Quipt Home Medical Corp. (TSXV:QIPT) provides in-home clinical respiratory care and disease management solutions across the United States, delivering technology-enabled durable medical equipment and services for patients with chronic conditions including cardio-pulmonary diseases, sleep disorders, mobility challenges, and other respiratory illnesses; core offerings encompass oxygen therapy, non-invasive ventilation, sleep apnea treatment via continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP) devices, airway clearance and secretion mobilization products, mobility aids, and comprehensive end-to-end respiratory monitoring and telehealth-supported chronic disease management. Founded as Protech Home Medical Corp. and renamed Quipt Home Medical Corp. in May 2021, the company is headquartered in Wilder, Kentucky, with operations spanning multiple states through subsidiaries and an expanding network of service locations focused on post-acute care coordination for healthcare providers, payers, and patients. Recent strategic developments include the June 2025 acquisition of a Ballad Health-owned durable medical equipment provider, which added respiratory, oxygen, mobility, and home medical products while establishing a preferred provider agreement across 20 hospitals in four states to enhance post-acute care integration; an August 2025 joint venture acquiring 60% of Hart Medical Equipment for $60 million in added revenue, expanding into Michigan and northern Ohio with 29 locations and partnerships with three major health systems; the launch of a new Medicare-approved airway clearance device in 2025 to target higher-acuity respiratory patients; and ongoing product portfolio diversification alongside capital allocation for share buybacks and further healthcare system M&A.